Antimicrobial Peptides are Promising Antibiotic Compounds
The development of novel methods to overcome the inevitable resistance that develops with common antibiotics is an important area of current research. Recent studies have shown that antimicrobial peptides (AMPs) have the potential to become excellent antibiotic compounds toward a broad-spectrum of Gram-positive and Gram-negative bacteria with less potential for bacterial resistance than conventional antibiotics (Shai, 2004). Because these compounds are highly selective toward bacteria and bacteria have difficulty in developing resistance to their effects, a large number of studies have focused on designing potent AMPs for potential pharmaceutical applications (Maloy Biopolymers; Marsh et al., 2009). One of the designed peptides, MSI-78 (also known as pexiganan), rose successfully to phase II clinical trials for treating infection in the case of diabetic foot ulcer (Gottler and Ramamoorthy, 2009).
Composition of Membranes is Key to Amp Selectivity
Bacteria have difficulty in developing resistance to AMPs because the toxicity of AMP is mostly mediated by a non-specific process rather than by an interaction with a specific protein target. Most AMPs lyse bacteria by directly interacting with the lipid bilayer of the bacterial cell membrane and disrupting the lipid bilayer structure (Oren and Shai, 1998; Epand and Vogel, 1999; Shai, 2002; Bechinger, 2011). The development of more potent and selective AMPs requires that the molecular basis of activity and selectivity be understood. Substantial progress has been made in recent years in this area, particularly using cutting-edge solid-state NMR spectroscopy to provide insights into the mechanisms of membrane disruption by AMPs (Bechinger, 1999; Durr et al., 2006; Bhattacharjya and Ramamoorthy, 2009; Ramamoorthy, 2009; Nguyen et al., 2011). For example, the high-resolution 3D structure, membrane orientation, and mechanism of membrane disruption are reported for several important peptides including LL-37 (Wildman et al., 2003; Porcelli et al., 2008), MSI-78 (Hallock et al., 2003), MSI-594 (Ramamoorthy et al., 2006; Bhunia et al., 2009), and pardaxin (Hallock et al., 2002; Porcelli et al., 2004; Bhunia et al., 2010). Biophysical studies have also revealed the role of anionic lipids, (Thennarasu et al., 2010) cholesterol, and lipopolysaccharides (Bhunia et al., 2009, 2010; Domadia et al., 2010) in Gram-negative bacteria on the antimicrobial activities of these AMPs. In addition, substantial progress has been in understanding the molecular determinants of AMP activity. For example, recent studies have shown the ability to form oligomeric aggregates in the cell membrane enhances the potency of an AMP (Toke et al., 2004; Tremouilhac et al., 2006; Marquette et al., 2008; Ramamoorthy et al., 2008; Strandberg et al., 2008). Studies have also shown that the presence of d-amino acids (Mangoni et al., 2006) and disulfide bridges (Dhople et al., 2006) can enhance resistance against proteolytic degradation without affecting the antimicrobial activity.
From these studies, a picture of how AMPs preferentially target bacteria has begun to emerge. The selectivity of AMPs therefore largely lies in their ability to distinguish between prokaryotic and eukaryotic membranes (Glukhov et al., 2005; Epand et al., 2006b). Biophysical studies have shown the importance of two factors in the membrane selectivity of an AMP (Figure 1A): (a) the electrostatic interaction between a cationic AMP and the acidic bacterial membrane which is composed of about ∼25% anionic lipids (POPS, POPG, and/or cardiolipin; Glukhov et al., 2005; van Meer et al., 2008; Epand et al., 2010) and (b) the presence of a large amount of cholesterol in a eukaryotic cell membrane which inhibits membrane disruption by rigidifying the lipid bilayer structure (Benachir et al., 1997; Matsuzaki, 1999; Glukhov et al., 2005; Epand et al., 2006a; Verly et al., 2008). These factors controlling the membrane selectivity of AMPs can also be exploited for other pharmaceutical targets. For example, several AMPs have been shown to have anticancer activities; this property has been attributed to the presence of anionic lipids in the outer leaflet of the cancer cell plasma membrane (Hoskin and Ramamoorthy, 2008). Similarly, most AMPs also kill fungi, protozoa, and even enveloped viruses, which all show a lipid distribution different than a normal eukaryotic cell (Oren and Shai, 1998; Epand and Vogel, 1999; Shai, 2002; Bechinger, 2011; Nguyen et al., 2011; Pius et al., 2012). Despite this progress in understanding the molecular determinants of AMP activity, there are still unresolved questions, particularly with regards to the preferential targeting of bacterial membranes. While the role of anionic lipids in membrane targeting of AMPs is well established, the role of cholesterol is still not clear. Accordingly, this opinion article focuses on the distinct roles of cholesterol in homogenous versus heterogeneous lipid bilayers.
Figure 1
Cholesterol is Believed to Play a Role in Bacterial Selectivity of AMPs
One of the major differences between bacterial and eukaryotic cell membranes is the presence of a large amount of cholesterol in eukaryotic cell membranes and a complete absence in bacterial cell membranes (Figure 1A). Cholesterol has been shown to protect human erythrocytes from attack by magainin 2 (Matsuzaki et al., 1995b). Similar studies on model membranes have demonstrated that the presence of cholesterol reduces AMP binding and suppresses the disruption of lipid bilayer structure by AMPS (Feigin et al., 1995; Matsuzaki et al., 1995a; Tytler et al., 1995; Raghuraman and Chattopadhyay, 2004; Glukhov et al., 2005; Verly et al., 2008; Wu et al., 2010). Solid-state NMR studies have provided high-resolution insights into the role of cholesterol against the function of several AMPs (Benachir et al., 1997; Wildman et al., 2003; Ramamoorthy et al., 2010). Cholesterol is known to increase membrane cohesion and mechanical stiffness (Evans and Waugh, 1977; Henriksen et al., 2006) which may resist the membrane bending required for many AMPs to function (Allende et al., 2005). This interaction reduces the tilt of the paradaxin helix relative to the bilayer normal, which in turn reduces the stability of the paradaxin pore (Ramamoorthy et al., 2010). However, for most AMPs a noticeable inhibitory effect of cholesterol is only noticeable after the formation of liquid ordered lipid phase at high concentrations of cholesterol (∼20%; McHenry et al., submitted) which suggests it may be due to an indirect effect due to a modulation of membrane properties rather than a direct interaction (Feigin et al., 1995). Despite these advances, the actual reason for the reduced affinity of many AMPs for cholesterol containing membranes is not fully understood. As noted above, this is traditionally been interpreted as a consequence of the increased acyl chain order in the liquid ordered phase of cholesterol containing membranes. In this context, it is interesting to compare cholesterol's effects on AMPs which do not clearly prefer the disordered liquid crystalline lipid phase or ordered gel phase. Surprisingly, cholesterol still strongly inhibits these peptides, which suggests an additional factor, such as dehydration of the headgroup region (M’Baye et al., 2008) is partially responsible for cholesterol's effect.
Cholesterol Loses Its Effectiveness in Inhibiting AMPs When Incorporated into Raft-Like Domains
While biophysical studies have shown the ability of cholesterol to suppress the action of an AMP against a homogeneous lipid bilayer, recent studies have revealed that cholesterol does not have this same effect in heterogeneous lipid systems (Pokorny and Almeida, 2005; Pokorny et al., 2006). Though few studies have looked at membrane disruption by AMPs in heterogeneous systems with phase separation [particularly in liquid ordered (lo) liquid-disordered (ld) domain coexistences often referred to as “lipid rafts”], two studies by the Almeida group demonstrated the permeabilizing activity of δ-lysin in raft-like palmitoyl-2-oleoylphosphatidylcholine/cholesterol/sphingomyelin (POPC/Chol/SM) mixtures (Pokorny and Almeida, 2005; Pokorny et al., 2006). These studies revealed that membrane permeabilization by δ-lysin occurs exclusively in the ld phase in membranes with ld − lo phase segregation and that the localization of δ-lysin to the ld phase results in greater membrane disruption than would be expected in the absence of phase segregation. Our own group recently demonstrated that this important effect occurs among a diverse set of AMPs (MSI-78, MSI-594, MSI-843, and MSI-367) encompassing several membrane disruptive mechanisms (McHenry et al., submitted). These combined results indicate that the phase separation naturally occurring in eukaryotic membranes is likely to nullify the effect of cholesterol against membrane disruption by AMPs. This surprising result suggests either cholesterol is not as important in determining the selectivity of AMPs toward bacterial membranes as once supposed, or unknown additional factors mitigate this effect in eukaryotic cells.
The mechanism of action of an AMP in a heterogeneous lipid system is depicted in Figure 1B. These results suggest that raft formation localizes the concentration of cholesterol in the cell membrane in such a way that non-raft domains of the cell membrane can be easily disrupted by AMPs and toxins. It is also possible that the phase behavior of the membrane and the physicochemical properties of the boundaries connecting the ordered and disordered domains play important roles in the membrane disruption process by AMPs. For instance, paradaxin has been shown to segregate a homogeneous membrane into cholesterol rich and cholesterol poor domains (Epand et al., 2006a). While the AMPs that have been investigated so far function by the non-specifically mechanically disrupting the membranes (carpet, detergent-type, or toroidal-pore formation) mechanism (Figure 1A), it is unclear how AMPs resembling more traditional ion channels (barrel-stave mechanism) would interact with heterogeneous lipid systems (Figure 1B). Therefore, it is important to further investigate the interaction of a variety of AMPs with more heterogeneous lipid systems.
Future Scope
While the development of AMPs for antibiotic applications is highly important, it is essential to understand the origin of their bacterial selectivity. As mentioned above, recent studies have shown that AMPs easily disrupt the structure of heterogeneous lipid systems, and therefore cholesterol is unlikely to play a major role in reducing the toxicity or increasing the selectivity of AMPs. Since a natural eukaryotic cell membrane contains heterogeneous lipid systems and domains, cholesterol poor domains must be easily disruptable by an AMP. Further studies probing the role of cholesterol in different types of lipid bilayers with a variety of AMPs are essential to better understand the exact role of cholesterol on the toxicity and selectivity of AMPs. Such studies would aid in the design of more efficient AMPs.
Statements
Acknowledgments
We thank the present and past members of the Ramamoorthy lab for their contributions to this study. This study was supported by funds from NIH (to Austin J. McHenry).
References
1
AllendeD.SimonS. A.McintoshT. J. (2005). Melittin-induced bilayer leakage depends on lipid material properties: evidence for toroidal pores. Biophys. J.88, 1828–1837.10.1529/biophysj.104.049817
2
BechingerB. (1999). The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy. Biochim. Biophys. Acta1462, 157–183.10.1016/S0005-2736(99)00205-9
3
BechingerB. (2011). Insights into the mechanisms of action of host defence peptides from biophysical and structural investigations. J. Pept. Sci.17, 306–314.10.1002/psc.1343
4
BenachirT.MonetteM.GrenierJ.LafleurM. (1997). Melittin-induced leakage from phosphatidylcholine vesicles is modulated by cholesterol: a property used for membrane targeting. Eur. Biophys. J.25, 201–210.10.1007/s002490050032
5
BhattacharjyaS.RamamoorthyA. (2009). Multifunctional host defense peptides: functional and mechanistic insights from NMR structures of potent antimicrobial peptides. FEBS J.276, 6465–6473.10.1111/j.1742-4658.2009.07357.x
6
BhuniaA.DomadiaP. N.TorresJ.HallockK. J.RamamoorthyA.BhattacharjyaS. (2010). NMR structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles mechanism of outer membrane permeabilization. J. Biol. Chem.285, 3883–3895.10.1074/jbc.M109.065672
7
BhuniaA.RamamoorthyA.BhattacharjyaS. (2009). Helical hairpin structure of a potent antimicrobial peptide MSI-594 in lipopolysaccharide micelles by NMR spectroscopy. Chemistry15, 2036–2040.10.1002/chem.200802635
8
DhopleV.KrukemeyerA.RamamoorthyA. (2006). The human beta-defensin-3, an antibacterial peptide with multiple biological functions. Biochim. Biophys. Acta1758, 1499–1512.10.1016/j.bbamem.2006.07.007
9
DomadiaP. N.BhuniaA.RamamoorthyA.BhattacharjyaS. (2010). Structure, interactions, and antibacterial activities of MSI-594 derived mutant peptide MSI-594F5A in lipopolysaccharide micelles: role of the helical hairpin conformation in outer-membrane permeabilization. J. Am. Chem. Soc.132, 18417–18428.10.1021/ja1083255
10
DurrU. H. N.SudheendraU. S.RamamoorthyA. (2006). Ll-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta1758, 1408–1425.10.1016/j.bbamem.2006.03.030
11
EpandR. F.MaloyW. L.RamamoorthyA.EpandR. M. (2010). Probing the “charge cluster mechanism” in amphipathic helical cationic antimicrobial peptides. Biochemistry49, 4076–4084.10.1021/bi100378m
12
EpandR. F.RamamoorthyA.EpandR. M. (2006a). Membrane lipid composition and the interaction of pardaxin: the role of cholesterol. Protein Pept. Lett.13, 1–5.10.2174/092986606774502063
13
EpandR. F.SchmittM. A.GellmanS. H.EpandR. M. (2006b). Role. Of membrane lipids in the mechanism of bacterial species selective toxicity by two alpha/beta-antimicrobial peptides. Biochim. Biophys. Acta1758, 1343–1350.10.1016/j.bbamem.2006.01.018
14
EpandR. M.VogelH. J. (1999). Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta1462, 11–28.10.1016/S0005-2736(99)00198-4
15
EvansE. A.WaughR. (1977). Mechano-chemistry of closed, vesicular membrane systems. J. Colloid Interface Sci.60, 286–298.10.1016/0021-9797(77)90288-0
16
FeiginA. M.TeeterJ. H.BrandJ. G. (1995). The influence of sterols on the sensitivity of lipid bilayers to melittin. Biochem. Biophys. Res. Commun.211, 312–317.10.1006/bbrc.1995.1812
17
GlukhovE.StarkM.BurrowsL. L.DeberC. M. (2005). Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J. Biol. Chem.280, 33960–33967.10.1074/jbc.M507042200
18
GottlerL. M.RamamoorthyA. (2009). Structure, membrane orientation, mechanism, and function of pexiganan – a highly potent antimicrobial peptide designed from magainin. Biochim. Biophys. Acta1788, 1680–1686.10.1016/j.bbamem.2008.10.009
19
HallockK. J.LeeD. K.OmnaasJ.MosbergH. I.RamamoorthyA. (2002). Membrane composition determines pardaxin's mechanism of lipid bilayer disruption. Biophys. J.83, 1004–1013.10.1016/S0006-3495(02)75226-0
20
HallockK. J.LeeD. K.RamamoorthyA. (2003). MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys. J.84, 3052–3060.10.1016/S0006-3495(03)70031-9
21
HenriksenJ.RowatA. C.BriefE.HsuehY. W.ThewaltJ. L.ZuckermannM. J.IpsenJ. H. (2006). Universal behavior of membranes with sterols. Biophys. J.90, 1639–1649.10.1529/biophysj.105.067652
22
HoskinD. W.RamamoorthyA. (2008). Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta1778, 357–375.10.1016/j.bbamem.2007.11.008
23
MangoniM. L.PapoN.SaugarJ. M.BarraD.ShaiY. C.SimmacoM.RivasL. (2006). Effect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H. Biochemistry45, 4266–4276.10.1021/bi052150y
24
MarquetteA.MasonA. J.BechingerB. (2008). Aggregation and membrane permeabilizing properties of designed histidine-containing cationic linear peptide antibiotics. J. Pept. Sci.14, 488–495.10.1002/psc.966
25
MarshE. N. G.BuerB. C.RamamoorthyA. (2009). Fluorine-a new element in the design of membrane-active peptides. Mol. Biosyst.5, 1143–1147.10.1039/b909864j
26
MatsuzakiK. (1999). Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta1462, 1–10.10.1016/S0005-2736(99)00197-2
27
MatsuzakiK.MuraseO.FujiiN.MiyajimaK. (1995a). Translocation of a channel-forming antimicrobial peptide, magainin-2, across lipid bilayers by forming a pore. Biochemistry34, 6521–6526.10.1021/bi00010a034
28
MatsuzakiK.SugishitaK.FujiiN.MiyajimaK. (1995b). Molecular-basis for membrane selectivity of an antimicrobial peptide, magainin-2. Biochemistry34, 3423–3429.10.1021/bi00010a034
29
M'BayeG.MelyY.DuportailG.KlymchenkoA. S. (2008). Liquid ordered and gel phases of lipid bilayers: fluorescent probes reveal close fluidity but different hydration. Biophys. J.95, 1217–1225.10.1529/biophysj.107.127480
30
NguyenL. T.HaneyE. F.VogelH. J. (2011). The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol.29, 464–472.10.1016/j.tibtech.2011.05.001
31
OrenZ.ShaiY. (1998). Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers47, 451–463.10.1002/(SICI)1097-0282(1998)47:6<451::AID-BIP4>3.0.CO;2-F
32
PiusJ.MorrowM. R.BoothV. (2012). H-2 solid-state nuclear magnetic resonance investigation of whole Escherichia coli interacting with antimicrobial peptide MSI-78. Biochemistry51, 118–125.10.1021/bi201569t
33
PokornyA.AlmeidaP. F. F. (2005). Permeabilization of raft-containing lipid vesicles by delta-lysin: a mechanism for cell sensitivity to cytotoxic peptides. Biochemistry44, 9538–9544.10.1021/bi0506371
34
PokornyA.YandekL. E.ElegbedeA. I.HinderliterA.AlmeidaP. F. F. (2006). Temperature and composition dependence of the interaction of delta-lysin with ternary mixtures of sphingomyelin/cholesterol/popc. Biophys. J.91, 2184–2197.10.1529/biophysj.106.085027
35
PorcelliF.BuckB.LeeD. K.HallockK. J.RamamoorthyA.VegliaG. (2004). Structure and orientation of pardaxin determined by NMR experiments in model membranes. J. Biol. Chem.279, 45815–45823.10.1074/jbc.M405454200
36
PorcelliF.VerardiR.ShiL.Henzler-WildmanK. A.RamamoorthyA.VegliaG. (2008). NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in dodecylphosphocholine micelles. Biochemistry47, 5565–5572.10.1021/bi702036s
37
RaghuramanH.ChattopadhyayA. (2004). Interaction of melittin with membrane cholesterol: a fluorescence approach. Biophys. J.87, 2419–2432.10.1529/biophysj.104.043596
38
RamamoorthyA. (2009). Beyond NMR spectra of antimicrobial peptides: dynamical images at atomic resolution and functional insights. Solid State Nucl. Magn. Reson.35, 201–207.10.1016/j.ssnmr.2009.03.003
39
RamamoorthyA.LeeD. K.NarasimhaswamyT.NangaR. P. R. (2010). Cholesterol reduces pardaxin's dynamics-a barrel-stave mechanism of membrane disruption investigated by solid-state NMR. Biochim. Biophys. Acta1798, 223–227.10.1016/j.bbamem.2009.08.012
40
RamamoorthyA.LeeD. K.SantosJ. S.Henzler-WildmanK. A. (2008). Nitrogen-14 solid-state NMR spectroscopy of aligned phospholipid bilayers to probe peptide-lipid interaction and oligomerization of membrane associated peptides. J. Am. Chem. Soc.130, 11023–11029.10.1021/ja802210u
41
RamamoorthyA.ThennarasuS.LeeD. K.TanA. M.MaloyL. (2006). Solid-state NMR investigation of the membrane-disrupting mechanism of antimicrobial peptides MSI-78 and MSI-594 derived from magainin 2 and melittin. Biophys. J.91, 206–216.10.1529/biophysj.105.073890
42
ShaiY. (2002). Mode of action of membrane active antimicrobial peptides. Biopolymers66, 236–248.10.1002/bip.10260
43
ShaiY. (2004). Antimicrobial peptides: a lesson from nature for future antibiotics. J. Pept. Sci.10, 112–112.
44
StrandbergE.KanithasenN.TiltakD.BurckJ.WadhwaniP.ZwernemannO.UlrichA. S. (2008). Solid-state NMR analysis comparing the designer-made antibiotic MSI-103 with its parent peptide PGLa in lipid bilayers. Biochemistry47, 2601–2616.10.1021/bi701944r
45
ThennarasuS.HuangR.LeeD. K.YangP.MaloyL.ChenZ.RamamoorthyA. (2010). Limiting an antimicrobial peptide to the lipid-water interface enhances its bacterial membrane selectivity: a case study of MSI-367. Biochemistry49, 10595–10605.10.1021/bi101394r
46
TokeO.O'ConnorR. D.WeldeghiorghisT. K.MaloyW. L.GlaserR. W.UlrichA. S.SchaeferJ. (2004). Structure of (KIAGKIA)(3) aggregates in phospholipid bilayers by solid-state NMR. Biophys. J.87, 675–687.10.1529/biophysj.103.032706
47
TremouilhacP.StrandbergE.WadhwaniP.UlrichA. S. (2006). Synergistic transmembrane alignment of the antimicrobial heterodimer PGLa/magainin. J. Biol. Chem.281, 32089–32094.10.1074/jbc.M604759200
48
TytlerE. M.AnantharamaiahG. M.WalkerD. E.MishraV. K.PalgunachariM. N.SegrestJ. P. (1995). Molecular-basis for prokaryotic specificity of magainin-induced lysis. Biochemistry34, 4393–4401.10.1021/bi00013a031
49
van MeerG.VoelkerD. R.FeigensonG. W. (2008). Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol.9, 112–124.10.1038/nrm2330
50
VerlyR. M.RodriguesM. A.DaghastanliK. R. P.DenadaiA. M. L.CuccoviaI. M.BlochC.FrezardF.SantoroM. M.Pilo-VelosoD.BemquererM. P. (2008). Effect of cholesterol on the interaction of the amphibian antimicrobial peptide DD K with liposomes. Peptides29, 15–24.10.1016/j.peptides.2007.10.028
51
WildmanK. A. H.LeeD. K.RamamoorthyA. (2003). Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry42, 6545–6558.10.1021/bi0273563
52
WuG. Q.WuH. B.FanX. B.ZhaoR.LiX. F.WangS. L.MaY. H.ShenZ. L.XiT. (2010). Selective toxicity of antimicrobial peptide s-thanatin on bacteria. Peptides31, 1669–1673.10.1016/j.peptides.2010.03.036
Summary
Keywords
Antimicrobial peptide, Selectivity, Cholesterol, Lipid bilayer, membrane disruption
Citation
Brender JR, McHenry AJ and Ramamoorthy A (2012) Does Cholesterol Play a Role in the Bacterial Selectivity of Antimicrobial Peptides?. Front. Immun. 3:195. doi: 10.3389/fimmu.2012.00195
Received
14 June 2012
Accepted
21 June 2012
Published
17 July 2012
Volume
3 - 2012
Edited by
Mark W. Robinson, University of Technology, Australia
Copyright
© 2012 Brender, McHenry and Ramamoorthy.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
*Correspondence: ramamoor@umich.edu
This article was submitted to Frontiers in Molecular Innate Immunity, a specialty of Frontiers in Immunology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.